| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
22064 |
| Drug |
Teclistamab |
| Brand |
Tecvayli® |
| Indication |
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
| Rapid review commissioned |
20/09/2022 |
| Rapid review completed |
03/11/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teclistamab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/11/2022 |
| Pre-submission consultation with Applicant |
24/01/2023 |
| Full submission received from Applicant |
18/05/2023 |
| Preliminary review sent to Applicant |
06/02/2024 |
| NCPE assessment re-commenced |
07/03/2024 |
| Follow-up to preliminary review sent to Applicant |
16/04/2024 |
